title: No differences of immune activation and microbial translocation among HIV-infected children receiving combined antiretroviral therapy or protease inhibitor monotherapy.
abstract: This is a cross-sectional study of 15 aviremic chronic HIV-infected children revealing no differences in immune activation (IA; HLA-DRCD38 CD4 and CD8 T cells, and sCD14) and microbial translocation (MT; lipopolysaccharides (LPS) and 16S rDNA) among HIV-infected patients under combined antiretroviral treatment (cART; n = 10) or ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv; n = 5). In both cases, IA and MT were lower in healthy control children (n = 32). This observational study suggests that ritonavir boosted protease inhibitor monotherapy (mtPI/rtv) is not associated with an increased state of IA or MT as compared with children receiving cART.
authors: From the Unidad de Enfermedades Infecciosas e Inmunopatologias, Hospital Infantil Virgen del Rocio, Instituto de Biomedicina de Sevilla (LF-N, LM, ON); Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío/Instituto de Biomedicina de Sevilla (IBiS), Sevilla (OJB-H, LL-C); ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; and Unitat d'Infectologia, Servei de Pediatria, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain (LM, AN-J, CF).
authors: Lola
authors: L
authors: Falcon-Neyra
authors: Omar J
authors: OJ
authors: Benmarzouk-Hidalgo
authors: Lola
authors: L
authors: Madrid
authors: Antoni
authors: A
authors: Noguera-Julian
authors: Claudia
authors: C
authors: Fortuny
authors: Olaf
authors: O
authors: Neth
authors: Luis
authors: L
authors: López-Cortés
mesh_terms: D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018988:Bacterial Translocation / Q000187:drug effects*; D016022:Case-Control Studies; D002648:Child; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects*; D008297:Male; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D044966:Anti-Retroviral Agents; D011480:Protease Inhibitors